| Description | Etofylline clofibrate has a hypolipidemic and antithrombotic effect and it also has an agonistic interaction with intimal PGI2. |
| In vivo | Etofylline clofibrate (p.o.; 12 mg/kg) has the moderate effect of a single dose (12% reduction in disaggregation time). It has a maximum reduction of 31 and 43% following 5 and 7 consecutive daily applications, respectively. |
| molecular weight | 420.85 |
| Molecular formula | C19H21ClN4O5 |
| CAS | 54504-70-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 52 mg/mL (123.56 mM), Sonication is recommended. |
| References | 1. Metz G, et al. Effect of etofylline clofibrate on experimental thrombus formation and prostacyclin activation. Arzneimittelforschung. 1986 Sep;36(9):1363-5. |